MAPT and Alzheimer disease: AβpE3−40/t-tau might be an effective and feasible candidate for blood-based screening of cerebral AD-related neuropathology aimed at identifying at-risk individuals that should be recommended for CSF and/or PET studies prior to clinical treatment planning.